Bai Yongli, Giguére Vincent
Molecular Oncology Group, McGill University Health Centre, Room H5-21, 687 Pine Avenue West, Montréal, Québec, Canada H3A 1A1.
Mol Endocrinol. 2003 Apr;17(4):589-99. doi: 10.1210/me.2002-0351. Epub 2003 Jan 16.
Estrogen receptor (ER)alpha and -beta interact with a variety of coactivator proteins, most notably members of the steroid receptor coactivator (SRC) family, and these interactions have been shown to be regulated by estrogenic ligands and growth factor signaling. Here, using fluorescence resonance energy transfer (FRET), the selectivity of different stimulants on ERalpha and -beta interactions with coactivator receptor interaction domains (RIDs) were examined in living cells. We first show that ERalpha and ERbeta homo- and heterodimers form in vivo independently of the presence of 17beta-estradiol (E2) or antiestrogens. We then demonstrate that E2 enhances interactions between ERalpha and the RIDs of SRC-1 and SRC-3, whereas the interaction between ERalpha with the SRC-2 RID is ligand independent. The transcriptionally inactive mutant ERalphaL539A showed no interaction with all three SRC RIDs. Similarly, treatment with the antagonists 4-hydroxytamoxifen and EM-652 abolished all interactions between ERalpha and the SRC RIDs. FRET data also demonstrate that, in contrast to ERalpha, ERbeta interacts with all three SRC RIDs in a ligand-independent manner. However, these interactions were further enhanced or stabilized by E2, whereas the antiestrogen EM-652 abolished all interactions. In the presence of both ERalpha and ERbeta, E2 treatment led to the recruitment of SRC RIDs to the nuclei. Finally, expression of the oncogenic activated ErbB-2/Neu protein specifically enhanced ERalpha but not ERbeta interactions with SRC RIDs to an extent similar to E2-stimulated interactions. In summary, using FRET, we demonstrated preferential interactions between ER isoforms and coactivators upon hormonal treatment and activation of a growth factor signal transduction pathway in living cells.
雌激素受体(ER)α和β与多种共激活蛋白相互作用,其中最显著的是类固醇受体共激活因子(SRC)家族成员,并且这些相互作用已被证明受雌激素配体和生长因子信号传导调节。在此,利用荧光共振能量转移(FRET)技术,在活细胞中检测了不同刺激物对ERα和β与共激活受体相互作用结构域(RID)相互作用的选择性。我们首先表明,ERα和ERβ的同二聚体和异二聚体在体内形成,与17β - 雌二醇(E2)或抗雌激素的存在无关。然后我们证明,E2增强了ERα与SRC - 1和SRC - 3的RID之间的相互作用,而ERα与SRC - 2 RID之间的相互作用则不依赖配体。转录无活性的突变体ERαL539A与所有三种SRC RID均无相互作用。同样,用拮抗剂4 - 羟基他莫昔芬和EM - 652处理消除了ERα与SRC RID之间的所有相互作用。FRET数据还表明,与ERα相反,ERβ以不依赖配体的方式与所有三种SRC RID相互作用。然而,这些相互作用被E2进一步增强或稳定,而抗雌激素EM - 652消除了所有相互作用。在同时存在ERα和ERβ的情况下,E2处理导致SRC RID募集到细胞核。最后,致癌激活的ErbB - 2/Neu蛋白的表达特异性增强了ERα与SRC RID的相互作用,但对ERβ没有影响,其增强程度与E2刺激的相互作用相似。总之,利用FRET技术,我们证明了在激素处理和活细胞中生长因子信号转导途径激活后,ER亚型与共激活因子之间存在优先相互作用。